DanDi Bioscience

https://www.edaily.co.kr/news/read?newsId=01679366632296120&mediaCodeNo=257&OutLnkChk=Y   

This post has been translated from the original article dated 4/14/2022. 

[Edaily Reporter Hyeshin Ahn] HLB Science (formerly Dandi Bioscience), which is developing a next-generation sepsis treatment, announced on the 14th that it had xxxselected Shinhan Investment Corp. as the manager for the listing on the KOSDAQ transfer. HLB Science is listed on KONEX as a subsidiary of HLB Global (formerly Next Science).

HLB Science is a peptide-based new drug development company established in 2016 by Professor Park Young-min of the Department of Immunology at Konkuk University Graduate School of Medicine, who is the top authority on infectious diseases in Korea. It is being developed as a first-in-class new drug.

Sepsis treatment 'DD-S052' is a new concept with a dual mechanism of action that not only directly kills super bacteria, the cause of sepsis, but also suppresses the cytokine storm by removing endotoxin derived from Gram-negative bacteria. As a treatment, phase 1 clinical trials are scheduled to begin in France in the middle of this year.

HLB Science plans to maximize corporate value and expand clinical trials to a global scale by transferring technology to a multinational pharmaceutical company before and after entering phase 2 clinical trials of 'DD-S052'.

Park Young-min, CEO of HLB Science, said, “The main cause of sepsis is infection by microorganisms, and many patients are dying due to an excessive inflammatory immune response and subsequent immune paralysis reaction. While it only removes the causative bacteria, DD-S052 will dramatically increase the survival rate by eliminating the causative bacteria of sepsis and neutralizing endotoxin released by the causative bacteria.”

He added, “We will repay the support and expectations of our shareholders by not only entering phase 1 clinical trials in France this year, but also succeeding in listing before listing on the KOSDAQ and exporting technology in the second half of next year.”